EXTINA: FDA Approved Topical Application for Treatment of Seborrheic Dermatitis

Dosing, Side Effects and Contraindications

Treating skin disorders can be a challenging for not only the skin disorder sufferer but for the dermatologist also. With skin disorders varying from those associated with fungal infections to those associated with autoimmune complications, so the treatments are also just as varied. Fortunately, for many skin disorder sufferers, the treatment regimen is often as simple as the use of a topical prescription ointment or cream.

For example, to remedy the complications associated with a skin disorder such as seborrheic dermatitis, Stiefel Laboratories manufactures an FDA approved prescription topical foam known as EXTINA. EXTINA has shown to be effective at controlling spread and outbreaks associated with seborrheic dermatitis through a simple topical application.

Dosing of EXTINA, in the treatment of seborrheic dermatitis, is recommended as either a 50 gram or 100 gram container containing 2% ketoconazole, applied twice daily. As a general rule, maximum therapeutic benefit is achieved in as little as four weeks.

As with most FDA approved drugs, the use of EXTINA, in the treatment of the skin disorder, seborrheic dermatitis, does not come without side effects. As a general rule, most side effects will dissipate as treatment reduces the complications associated with seborrheic dermatitis and the abnormal development of skin lesions and rash. When using EXTINA, side effects most commonly experienced by patients include redness, swelling and pain, or burning, at the site of foam application. If symptoms seem excessive while using EXTINA, resulting in extreme pain, swelling or breakdown of skin or tissue, it may be necessary to seek out the medical attention of a healthcare professional.

Contraindications, in the use of EXTINA, in treating seborrheic dermatitis, are very limited with general precautions to limit use to only those patients who are over the age of 12. As a Category C drug, women who are pregnant, or may become pregnant, are cautioned in the use of EXTINA, in treating seborrheic dermatitis, as the topical foam may be detrimental to a developing fetus when, or if, leaked into the system.